Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3Urinary Bladder Neoplasms 1Surgery 1Stress, Psychological 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Ductal Adenocarcinoma 1Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer 1Multiple Myeloma 1Medulloblastoma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Intermittent Fasting 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1Breast Cancer Invasive 1

Interventions

Tamoxifen 5Specimen Handling 4exemestane 2Letrozole 2Anastrozole 2fezolinetant 1elacestrant 1Testosterone 1Surgical Procedures, Operative 1Omacor 1Neoadjuvant Therapy 1FAPI-46 1Biopsy 14-hydroxy-N-desmethyltamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Intraductal, Noninfiltrating × Neoadjuvant Therapy × 30 days × Clear all
NCT01272037 2026-06-03

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
5,018 enrolled 14 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡